# NEST-1 (NCT05571293)

> Combination Immunotherapy in Colorectal Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05571293
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Weill Medical College of Cornell University
- Conditions: Colorectal Neoplasms
- Interventions: Botensilimab; Balstilimab
- Enrollment: 26
- Primary outcome: Cohort A and B: Pathological Overall Response (pOR) Rate Determined by Analysis of Tissue Resected During Surgery Reported by Cohort
- Primary outcome: Cohort A: Number of Participants Who Experience Potentially Treatment-related SAEs According to the Common Terminology Criteria for Adverse Events (CTCAE) v5.0 at 90 Days Following the Last Treatment With Balstilimab or Botensilimab
- Primary outcome: Cohort A: Number of Participants Who Experience Treatment-related Complications Leading to Delays of 12 Weeks or More in Surgery After Treatment Initiation (Day 0)
- Primary outcome: Cohort C: Composite Rate of Clinical Complete Response or Major Pathological Response at 6 Months

## Commentary we found

- X threads: 38
- YouTube: 8
- Podcasts: 8
- X videos: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=nest-1-nct05571293

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05571293", "email": "<work email>"}; the inbox owner confirms by the emailed link.